Analyst Price Targets — AGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 29, 2024 11:34 am | Emily Bodnar | H.C. Wainwright | $7.00 | $3.57 | StreetInsider | H.C. Wainwright Reiterates Neutral Rating on Agenus Inc. (AGEN) |
| July 19, 2024 8:55 am | Biren Amin | Jefferies | $7.00 | $5.99 | StreetInsider | Jefferies Downgrades Agenus Inc. (AGEN) to Hold |
| July 19, 2024 4:59 am | Colleen Kusy | Robert W. Baird | $8.00 | $7.30 | TheFly | Agenus downgraded to Neutral from Outperform at Baird |
| July 18, 2024 12:33 pm | Emily Bodnar | H.C. Wainwright | $9.00 | $7.98 | TheFly | Agenus downgraded to Neutral from Buy at H.C. Wainwright |
| July 1, 2024 6:42 am | Emily Bodnar | H.C. Wainwright | $20.00 | $8.38 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Agenus Inc. (AGEN) |
Latest News for AGEN
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The…
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGEN.
U.S. House Trading
No House trades found for AGEN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.